Daewoong Pharmaceuticals and inno.N, the two Korean frontrunners in potassium-competitive acid blocker (P-CAB) drugs for gastroesophageal reflux disease (GERD), are fiercely competing to carve out a larger share in the global market.inno.N won the title of the first Korean company to develop a new d
Industry watchers are paying attention to whether Daewoong Pharmaceutical will obtain the marketing approval for Fexuprazan, a gastroesophageal reflux treatment.This month, analysts at local investment banks began to raise anticipation for the release of Fexuprazan.Daewoong is waiting for the Minist
DeepBio said that Stanford University’s research team has released study results on DeepDx-Prostate, the company’s deep learning-based software that diagnoses prostate cancer, at the annual meeting of the American Urological Association (AUA).The researchers at Stanford University School of Medicine
The Ministry of Food and Drug Safety and the Korea Customs Service caught 110,000 illegal drugs imported directly from overseas, totaling 69.6 billion won ($58.6 million) over the past five years, a lawmaker said.The two agencies confiscated illegal drugs worth 9.1 billion won last year, according t
Hugel, a Korean aesthetics and therapeutics developer, said the European Medicines Agency (EMA) has completed an on-site inspection of its plant in Chuncheon, Gangwon Province, manufacturing its botulinum toxin (BTX) brand, Letybo.The plant produces more than five million BTX vials a year with the l
An international medical journal published the meta-analysis of studies, including the cardiovascular safety trial of Hanmi Pharmaceutical’s investigational antidiabetic drug, efpeglenatide.Industry watchers are paying attention to whether the publication will be a turning point for the development
The government has extended the current distancing rules for another two weeks ahead of transitioning into the more relaxed "live-with-covid" system from November.Accordingly, the Seoul metro region will be under the Level 4 distancing measures and the non-capital area under Level 3 measures until O
With the global supply chain under duress due to the protracted Covid-19 pandemic, Korean pharmaceutical companies are having difficulty obtaining raw materials, leading to some medicines going out of stock, industry sources said.For example, Yuhan Corp's constipation treatments Portalac powder and
Daewoong Pharmaceutical said it has signed an agreement with Aghrass Healthcare Limited, a United Arab Emirates (UAE)-based company, to license out gastroesophageal reflux treatment, Fexuprazan.Under the accord, Aghrass Healthcare Limited will license and sell Fexuprazan in six Middle Eastern nation
Besremi (ropeginterferon alfa-2b), developed by Taiwanese drugmaker Pharma Essentia, obtained marketing approval in Korea. It is a next-generation interferon that acts directly on hematopoietic stem cells to treat polycythemia vera fundamentally.On Wednesday, the Ministry of Food and Drug Safety app
Novartis Korea said that it has confirmed that Certican, its transplant immunosuppressant, preserves renal function, reduces viral infection, and has immunosuppressive efficacy in Asian kidney transplant patients, through a sub-analysis of the TRANSFORM study.According to the company, the TRANSFORM
EuBiologics is struggling to get a comparative vaccine to conduct a phase 3 trial of a Covid-19 vaccine, industry officials said.A comparative vaccine is essential for a comparative immunogenicity study because a vaccine candidate should prove its non-inferiority to the authorized vaccine.Compared t
A new gastrointestinal (GI) disorder treatment, developed by Yuhan Corp. and licensed out to a U.S. biotech firm, won the FDA approval for a Phase 2a trial.At the time of the licensing agreement, Yuhan received the U.S. partner company’s common stock in an upfront payment. The market is paying atten
Olix Pharmaceutical said it has signed a licensing and cooperative agreement with China’s Jiangsu Hansoh Pharmaceuticals Group to research and develop siRNA (small interfering ribonucleic acid) treatments.Under the accord, the two companies plan to discover therapeutic substances for cardiovascular
CureVac said it has decided to stop developing its first-generation mRNA Covid-19 vaccine candidate, CVnCoV, due to disappointing efficacy in phase 3 clinical trials and focus on a more promising second-generation vaccine with GSK.The company expected to get approval for CVnCoV in the second quarter
The Ministry of Food and Drug Safety ordered Hana Pharm to temporarily suspend its narcotics products such as anesthetics and pain relievers.Expecting the administrative punishment will take a significant toll on its sales, the company said it would take legal actions against the MFDS. In a public f
Novo Nordisk has started a clinical trial of semaglutide, a second-generation treatment for obesity after Saxenda (liraglutide), tailored for the Korean population. Saxenda is the leading obesity treatment in Korea in terms of sales.On Sept. 30, the Ministry of Food and Drug Safety approved a phase
Cellid, a developer of virus vector Covid-19 vaccine candidate, AdCLD-CoV19-1, said it has joined the COVAX Marketplace that allocates raw materials for vaccines.The innovative market coordinated by COVAX provides suppliers with a platform to allocate or reallocate unused materials for vaccines, mob
Pharmaceutical companies are actively working with drug delivery systems (DDS) companies to develop long-acting injections.Long-acting injections are drawing much attention because they are regarded as a new “growth engine” that can overcome the shortcomings of existing treatments.The development of
LegoChem Bioscience said it has entered into a research collaboration and license option agreement to develop an antibody-drug conjugate (ADC) treatment with a Chinese biopharmaceutical firm.However, the company did not name which Chinese company, citing a contractual term.Under the accord, the two